Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905

Naomi Winick; Paul L. Martin; Meenakshi Devidas; Jonathan Shuster; Michael J. Borowitz; W. Paul Bowman; Eric Larsen; Jeanette Pullen; Andrew Carroll; Cheryl Willman; Stephen P. Hunger; William L. Carroll; Bruce M. Camitta

doi:10.1038/s41375-019-0642-2

Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905

Naomi Winick, Paul L. Martin, Meenakshi Devidas, Jonathan Shuster, Michael J. Borowitz, W. Paul Bowman, Eric Larsen, Jeanette Pullen, Andrew Carroll, Cheryl Willman, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m²) vs. 4-h (2 g/m²) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = 0.002, whereas MTX administration did not; 4-h 80.8 ± 1.9%; 24-h 81.4 ± 1.9% (p = 0.7780). Overall survival (OS) at 10 years did not differ with DI: 91.4 ± 1.6% vs. 90.9 ± 1.7% (p = 0.25) without but was higher with the 24-h MTX infusion; 4-h 91.1 ± 1.4%; 24-h 93.9 ± 1.2% (p = 0.0209). MRD predicted outcome; 10-year CCR 87.7 ± 2.2 and 82.1 ± 2.5% when MRD was <0.01% with/without DI (p = 0.007) and 54.3 ± 8% and 44 ± 8% for patients with MRD ≥ 0.01% with/without DI (p = 0.11). DI improved CCR for patients with B-ALL with and without end induction MRD.

Original language	English (US)
Pages (from-to)	1006-1016
Number of pages	11
Journal	Leukemia
Volume	34
Issue number	4
DOIs	https://doi.org/10.1038/s41375-019-0642-2
State	Published - Apr 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-019-0642-2

Cite this

Winick, N., Martin, P. L., Devidas, M., Shuster, J., Borowitz, M. J., Paul Bowman, W., Larsen, E., Pullen, J., Carroll, A., Willman, C., Hunger, S. P., Carroll, W. L., & Camitta, B. M. (2020). Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905. Leukemia, 34(4), 1006-1016. https://doi.org/10.1038/s41375-019-0642-2

Winick, N, Martin, PL, Devidas, M, Shuster, J, Borowitz, MJ, Paul Bowman, W, Larsen, E, Pullen, J, Carroll, A, Willman, C, Hunger, SP, Carroll, WL & Camitta, BM 2020, 'Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905', Leukemia, vol. 34, no. 4, pp. 1006-1016. https://doi.org/10.1038/s41375-019-0642-2

@article{d30f9cfb6fb24345b865fc032ecf5d0a,

title = "Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children{\textquoteright}s Oncology Group Studies P9904 and P9905",

abstract = "The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m2) vs. 4-h (2 g/m2) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = 0.002, whereas MTX administration did not; 4-h 80.8 ± 1.9%; 24-h 81.4 ± 1.9% (p = 0.7780). Overall survival (OS) at 10 years did not differ with DI: 91.4 ± 1.6% vs. 90.9 ± 1.7% (p = 0.25) without but was higher with the 24-h MTX infusion; 4-h 91.1 ± 1.4%; 24-h 93.9 ± 1.2% (p = 0.0209). MRD predicted outcome; 10-year CCR 87.7 ± 2.2 and 82.1 ± 2.5% when MRD was <0.01% with/without DI (p = 0.007) and 54.3 ± 8% and 44 ± 8% for patients with MRD ≥ 0.01% with/without DI (p = 0.11). DI improved CCR for patients with B-ALL with and without end induction MRD.",

author = "Naomi Winick and Martin, {Paul L.} and Meenakshi Devidas and Jonathan Shuster and Borowitz, {Michael J.} and {Paul Bowman}, W. and Eric Larsen and Jeanette Pullen and Andrew Carroll and Cheryl Willman and Hunger, {Stephen P.} and Carroll, {William L.} and Camitta, {Bruce M.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2020",

month = apr,

doi = "10.1038/s41375-019-0642-2",

language = "English (US)",

volume = "34",

pages = "1006--1016",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL

T2 - Children’s Oncology Group Studies P9904 and P9905

AU - Winick, Naomi

AU - Martin, Paul L.

AU - Devidas, Meenakshi

AU - Shuster, Jonathan

AU - Borowitz, Michael J.

AU - Paul Bowman, W.

AU - Larsen, Eric

AU - Pullen, Jeanette

AU - Carroll, Andrew

AU - Willman, Cheryl

AU - Hunger, Stephen P.

AU - Carroll, William L.

AU - Camitta, Bruce M.

PY - 2020/4

Y1 - 2020/4

N2 - The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m2) vs. 4-h (2 g/m2) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = 0.002, whereas MTX administration did not; 4-h 80.8 ± 1.9%; 24-h 81.4 ± 1.9% (p = 0.7780). Overall survival (OS) at 10 years did not differ with DI: 91.4 ± 1.6% vs. 90.9 ± 1.7% (p = 0.25) without but was higher with the 24-h MTX infusion; 4-h 91.1 ± 1.4%; 24-h 93.9 ± 1.2% (p = 0.0209). MRD predicted outcome; 10-year CCR 87.7 ± 2.2 and 82.1 ± 2.5% when MRD was <0.01% with/without DI (p = 0.007) and 54.3 ± 8% and 44 ± 8% for patients with MRD ≥ 0.01% with/without DI (p = 0.11). DI improved CCR for patients with B-ALL with and without end induction MRD.

AB - The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m2) vs. 4-h (2 g/m2) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = 0.002, whereas MTX administration did not; 4-h 80.8 ± 1.9%; 24-h 81.4 ± 1.9% (p = 0.7780). Overall survival (OS) at 10 years did not differ with DI: 91.4 ± 1.6% vs. 90.9 ± 1.7% (p = 0.25) without but was higher with the 24-h MTX infusion; 4-h 91.1 ± 1.4%; 24-h 93.9 ± 1.2% (p = 0.0209). MRD predicted outcome; 10-year CCR 87.7 ± 2.2 and 82.1 ± 2.5% when MRD was <0.01% with/without DI (p = 0.007) and 54.3 ± 8% and 44 ± 8% for patients with MRD ≥ 0.01% with/without DI (p = 0.11). DI improved CCR for patients with B-ALL with and without end induction MRD.

UR - http://www.scopus.com/inward/record.url?scp=85075046448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075046448&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0642-2

DO - 10.1038/s41375-019-0642-2

M3 - Article

C2 - 31728054

AN - SCOPUS:85075046448

SN - 0887-6924

VL - 34

SP - 1006

EP - 1016

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this